Hi NYC., Another reason why dark Kynamro will fail versus Juxtapid.
Both exhibited the potential for liver tox as I've stated for the last seven years. However, the Kynamro arm in late stage trials presented "Abnormal Tissue Growth". Of course the easier to use Juxtapid will win in a heartbeat ! Now, I hope you have added to your holdings of Vical but be careful... all biotechs are risky! I see It's darkouttonight.. Good luck all. : )